Compare · MASI vs VRAY
MASI vs VRAY
Side-by-side comparison of Masimo Corporation (MASI) and ViewRay Inc. (VRAY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MASI and VRAY operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.36B, about 12.9x VRAY ($726.7M).
- MASI has hit the wire 1 time in the past 4 weeks while VRAY has been quiet.
- MASI has more recent analyst coverage (24 ratings vs 9 for VRAY).
- Company
- Masimo Corporation
- ViewRay Inc.
- Price
- $179.96+0.63%
- $0.03-39.95%
- Market cap
- $9.36B
- $726.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 1
- 0
- Recent ratings
- 24
- 9
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
ViewRay Inc.
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, Taiwan, the United Kingdom, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Latest MASI
- SEC Form SD filed by Masimo Corporation
- SEC Form SCHEDULE 13G filed by Masimo Corporation
- SEC Form 10-Q filed by Masimo Corporation
- Director Scannell Timothy J converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Director Lane Wendy E converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Chairman of the Board Brennan Michelle converted options into 1,225 shares, increasing direct ownership by 17% to 8,543 units (SEC Form 4)
- Chief Human Resources Officer Hellmann Elisabeth A converted options into 335 shares and covered exercise/tax liability with 121 shares (SEC Form 4) to satisfy tax liability
- Masimo Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- Masimo Shareholders Approve Acquisition by Danaher
- Amendment: SEC Form 10-K/A filed by Masimo Corporation
Latest VRAY
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- NUBURU Appoints Brian Knaley as new CEO
- SEC Form 25-NSE filed by ViewRay Inc.
- ViewRay Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by ViewRay Inc.
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- SEC Form 4 filed by Shah Sanket
- SEC Form 4 filed by Podbelski Adam Andrew